Jolanta Herrera
Internal Medicine · South Chesterfield, VANPI 1053418434
Payments from drug & device makers
Across 387 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$953
- Lilly USA, LLC$625
- AstraZeneca$515
- Amgen$471
- Bayer$439
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$395
- plus $3K from 27 others
What the payments were for
- Food & beverage$6,14799%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 93 | $953 |
| Lilly USA, LLC | 40 | $625 |
| AstraZeneca | 24 | $515 |
| Amgen(2 entities) | 21 | $471 |
| Bayer | 26 | $439 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $395 |
| Pfizer | 23 | $383 |
| GSK | 17 | $369 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $330 |
| Novo Nordisk | 16 | $298 |
| Supernus Pharmaceuticals, Inc. | 10 | $203 |
| Boehringer Ingelheim | 10 | $177 |
| Ardelyx, Inc. | 4 | $146 |
| Merck | 10 | $130 |
| Lundbeck LLC | 4 | $101 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Exact Sciences | 4 | $84 |
| Sanofi-aventis U.S. LLC | 5 | $72 |
| Novartis | 4 | $63 |
| Johnson & Johnson | 3 | $44 |
| Seqirus USA Inc | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 1 | $34 |
| Astellas Pharma US Inc | 1 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Dexcom, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Abbott | 1 | $13 |
| Athena Bioscience, LLC | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,223 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 99 | $134,029 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $101,290 |
| OzempicSemaglutide | 52 | $68,123 |
| EliquisApixaban | 80 | $64,966 |
| FarxigaDapagliflozin Propanediol | 56 | $56,535 |
| LinzessLinaclotide | 36 | $42,472 |
| TrulicityDulaglutide | 23 | $41,144 |
| JanuviaSitagliptin Phosphate | 39 | $40,254 |
| RybelsusSemaglutide | 23 | $32,062 |
| MounjaroTirzepatide | 23 | $31,910 |
| XareltoRivaroxaban | 29 | $30,915 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $30,336 |
| KerendiaFinerenone | 29 | $23,917 |
| EntrestoSacubitril/Valsartan | 15 | $16,380 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $12,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $177 | $143,236112 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $369 | $126,504169 claims |
| Novo NordiskOzempic, Rybelsus | $298 | $100,18575 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $625 | $73,05546 claims |
| PfizerEliquis | $383 | $64,96680 claims |
| AstraZenecaFarxiga | $515 | $56,53556 claims |
| AbbVieLinzess | $953 | $42,47236 claims |
| MerckJanuvia | $130 | $40,25439 claims |
| Johnson & JohnsonXarelto | $44 | $30,91529 claims |
| BayerKerendia | $439 | $23,91729 claims |
| NovartisEntresto | $63 | $16,38015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in South Chesterfield
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
- Sue BrownCharlottesville$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.